CardioNexa is building AI-powered clinical optimization infrastructure to make that vision real — starting with lipid management, and expanding across the full spectrum of cardiovascular prevention.
LipidNova identifies every ASCVD patient not meeting their LDL-C target, prioritizes them by clinical urgency, and delivers specific therapy recommendations aligned with the 2026 ACC/AHA Guidelines.
Every ASCVD patient scored and ranked by clinical urgency and impact. Your team works the highest-value patients first, every day.
Specific therapy recommendations citing the 2026 ACC/AHA guidelines — not generic advice. Actionable for each individual patient.
Morning command center showing today's priority patients with one-click actions: log calls, fax prior authorizations, copy EHR-ready notes.
Weekly population summary with therapy gap analysis, risk score distribution, and progress toward LDL-C goals across your ASCVD panel.
AI-powered natural language queries across your patient panel. "Show me patients with denied PAs" or "Who needs a PCSK9i?" — instant answers from your data.
Our AI agent processes patients overnight, auto-drafts EHR notes and PA fax templates, and pre-stages tomorrow's workqueue. Your team reviews and acts — the AI handles the preparation.
The treatments exist. The guidelines are published. But the gap between what we know and what patients actually receive is massive. CardioNexa combines AI automation with clinical expertise to close that gap — systematically, across every dimension of cardiovascular care.
We don't sell you a portal and walk away. CardioNexa's clinical team does the work — your practice gets the outcomes. Zero workflow change, zero portal fatigue.
Our closed-loop engine works for any condition where guidelines exist and adherence is low. Lipids today. Blood pressure, heart failure, and anticoagulation next. Same architecture, different parameters.
Our CEO spent decades in cardiac surgery seeing what happens when prevention fails. This isn't a tech company guessing at healthcare — it's clinicians building the future of cardiovascular care.
LipidNova is our first product — but the CardioNexa platform is designed to optimize every pillar of cardiovascular care.
LipidNova is CardioNexa's first product — a clinical decision engine that powers our managed lipid services. It processes your ASCVD patient population through a deterministic, guideline-aligned decision tree and produces prioritized, actionable recommendations for every patient.
CardioNexa integrates with your existing workflow — no EHR overhaul required.
We securely ingest your ASCVD patient population via FHIR R4 or CSV extract from your EHR. Encrypted in transit and at rest. BAA signed before any data sharing.
Our AI decision engine evaluates every patient against the 2026 ACC/AHA therapy ladder — risk stratification, LDL target determination, gap identification, and therapy optimization. An overnight AI agent pre-stages your workqueue and auto-drafts clinical documents. Every recommendation is auditable.
Your team receives a prioritized workqueue with specific, patient-level recommendations. Daily digest highlights the highest-urgency cases. Weekly executive reports track population progress.
Pharmacists review and act on recommendations with one-click EHR note copy, PA tracking, and activity logging. Actioned patients enter an 8-week follow-up cycle automatically.
CardioNexa was founded by a cardiac surgeon and a technologist who believe cardiovascular disease doesn't have to be the #1 killer — if we build the right systems.
Former Chief of Cardiac Surgery. Decades of experience in cardiovascular care and a firsthand understanding of the downstream consequences of unmanaged lipids.
Leads product, engineering, and operations. Built the clinical decision engine, cloud infrastructure, and HIPAA-compliant platform from the ground up.
Executive Chief of Cardiology, Care New England Health. Lecturer, Harvard Medical School. Provides clinical oversight and guideline validation for the CardioNexa platform.
Patient data security isn't a feature — it's the foundation. Every architectural decision prioritizes PHI protection.
AWS infrastructure with AES-256 encryption at rest, TLS 1.2+ in transit, per-client isolation, and a signed BAA with every cloud provider.
Pursuing SOC 2 Type II certification with continuous monitoring. Formal policies, quarterly access reviews, and automated evidence collection.
TOTP multi-factor authentication required for all users. 15-minute idle timeout, 8-hour absolute session limit, and session-level audit tracking.
Every PHI access, view, export, and action logged with user identity, timestamp, and IP address. 6-year retention per HIPAA requirements.
See how CardioNexa can improve LDL-C goal attainment across your ASCVD population.